Nikolai P Petrovsky - Public Health

Author Information

Nikolai P Petrovsky is a prominent researcher affiliated with the College of Medicine and Public Health at Flinders University in Adelaide, South Australia. He is also associated with Vaxine Pty Ltd, a biotechnology company located in Warradale, Adelaide. His work primarily focuses on vaccine development and public health, contributing significantly to advancements in immunology and infectious diseases.

Research Contributions

Nikolai P Petrovsky has made substantial contributions to the field of vaccine and drug design, particularly through the integration of artificial intelligence. In 2022 alone, he co-authored numerous papers exploring various aspects of vaccine development, including the design of novel adjuvants, computational drug repurposing against COVID-19, and the development of vaccines targeting specific pathogens like malaria and SARS-CoV-2. His research extends to the creation of a spike protein-based subunit SARS-CoV-2 vaccine for pets and the evaluation of vaccines for allergic asthma, showcasing his diverse expertise in immunology.

Aliases

Nikolai P Petrovsky is known by several aliases, including N Petrovsky and N. Petrovsky. These variations are commonly used in scientific publications and databases.

Publication and Citation Metrics

Metric	Value
Total Papers	337
Total Citations	15,331
H-index	54

Publications:

Artificial Intelligence in Vaccine and Drug Design.

DOI: 10.1007/978-1-0716-1884-4_6

Year: 2022

Stereoisomeric Pam2CS Based TLR2 Agonists: Synthesis, Structural Modelling and Activity as Vaccine Adjuvants

DOI: 10.1039/d1md00372k

Year: 2022

A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model

DOI: 10.1038/s41541-022-00457-1

Year: 2022

Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies

DOI: 10.3389/fmolb.2022.781039

Year: 2022

A Spike Protein-Based Subunit SARS-CoV-2 Vaccine for Pets: Safety, Immunogenicity, and Protective Efficacy in Juvenile Cats

DOI: 10.3389/fvets.2022.815978

Year: 2022

Safety and immunogenicity of SpikoGen®, an advax-cpg55.2-adjuvanted sars-cov-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

DOI: 10.1016/j.cmi.2022.04.004

Year: 2022

An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission

DOI: 10.1038/s41541-022-00450-8

Year: 2022

Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters

DOI: 10.1016/j.vaccine.2022.04.041

Year: 2022

Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model

DOI: 10.3389/fimmu.2022.828690

Year: 2022

Correction: Stewart et al. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms 2019, 7, 255

DOI: 10.3390/microorganisms10040757

Year: 2022

What is a Virus?

How can individuals contribute to water safety and public health?

What are the Symptoms?

What are the benefits of Telemedicine in Public Health?

What are the Symptoms of E. Coli Infection?

What is the Role of Food Safety in Global Health?

How Did the Pandemic Affect Mental Health?

How does SARS-CoV-2 spread?

Can I Still Get COVID-19 After Being Vaccinated?

How Do Vaccines Help in Controlling Coronaviruses?

Partnered Content Networks

Relevant Topics